Press Releases Valerio Therapeutics BOERSE MUENCHEN

Equities

C4X

FR0010095596

Market Closed - BOERSE MUENCHEN Other stock markets 03:43:16 2024-06-04 pm EDT			5-day change	1st Jan Change
0.1282 ^EUR	+25.93%		+25.93%	-15.38%

May. 22	Valerio Therapeutics S.A. Provides Clinical Development Update on Its Phase 1/2 VIO-01 Clinical Trial	CI
Apr. 30	Valerio Therapeutics Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Valerio Therapeutics : Reports Full Year 2023 Financial Results and Provides Clinical Development Updates	May. 24	PU
Valerio Therapeutics Provides Clinical Development Update on Its Phase 1/2 VIO-01 Clinical Trial	May. 22	BU
Valerio Therapeutics : Publication of the 2023 Annual Report	May. 22	PU
Valerio Therapeutics : Onxeo Receives Notice of Allowance from USPTO for New Patent Strengthening Protection of AsiDNA™ via Systemic Administration in the United States	May. 13	PU
Valerio Therapeutics : Onxeo Announces the Transfer of the Listing of its Shares to Euronext Growth Paris on December 15, 2020	May. 13	PU
Valerio Therapeutics : Annual financial and audit reports / Terms of availability of the annual financial report	Apr. 30	PU
Valerio Therapeutics Reports Full Year 2023 Financial Results and Provides Clinical Development Updates	Apr. 30	BU
Valerio Therapeutics : Reports Full Year 2023 Financial Results and Provides Clinical Development Updates	Apr. 30	PU
Valerio Therapeutics : Publication of the 2023 Annual Report	Apr. 30	PU
Onxeo : changes its name and becomes Valerio Therapeutics following approval by the Annual General Meeting of June 6, 2023	23-06-06	PU
Onxeo: Publication of the 2022 Annual Financial Report	23-04-28	BU
Onxeo Reports Full Year 2022 Financial Results and Provides Clinical Development Updates	23-04-24	BU
Onxeo will publish its full-year results on April 24, 2023	23-04-21	BU
Onxeo : Terms of availability of the preparatory documents for the GM	23-01-18	PU
Half-year liquidity contract statement for ONXEO	23-01-04	BU
Onxeo : Inside Information / News release on accounts, results	22-09-13	PU
Onxeo Reports its Half-Year 2022 Financial Results and Provides an Update on its Activities	22-09-13	BU
High-Grade Glioma Relapse in Children: Onxeo Announces the Enrollment of the First Patient in the Phase 1b/2 Clinical Study Conducted by the European ITCC Consortium and Sponsored by Institut Curie	22-09-01	BU
Onxeo Announces That Nasdaq Approved the Delisting of Its Shares From the First North Growth Market in Copenhagen	22-08-30	BU
Combined General Meeting of August 17, 2022: Onxeo Shareholders Approve Withdrawal From the Nasdaq First North Market in Copenhagen	22-08-17	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Valerio Therapeutics BOERSE MUENCHEN

Equities

C4X

FR0010095596

Press Releases

Filters